Cancer Biomarkers Market Size, Share, Trends – Analysis Report 2022
According to research report the global cancer biomarkers market to reach USD 20.4 billion by 2022. and is estimated to grow at a CAGR of 12.2% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
The
increasing prevalence of cancer, rising government support for research
on cancer biomarkers, growing use of biomarkers in drug discovery and
development, and increasing use of biomarker tests for diagnostic
purposes are the major factors that are driving the growth of this
market.
North America was the largest regional market for cancer biomarkers in 2016
North
America accounted for the largest share of the cancer biomarkers market
in 2017, followed by Europe. North America is the largest market for
cancer biomarkers majorly due to government support (in the US and
Canada) for the discovery and development of biomarkers, rising use of
biomarkers in drug discovery and development by pharmaceutical
companies, adoption of advanced omics technologies for biomarker
discovery, and the increasing demand for personalized medicine in the
region.
The genetic biomarkers segment is expected to grow at the highest CAGR during the forecast period
Based
on biomarker type, the cancer biomarkers market is segmented into
genetic biomarkers, protein biomarkers, and other biomarkers (cell,
viral, and carbohydrate biomarkers). During the forecast period, the
genetic biomarkers segment is estimated to grow at the highest CAGR
majorly due to advancements in high-throughput technologies, such as
next-generation sequencing, which have enhanced the speed and accuracy
of genetic biomarker discovery and diagnosis.
The breast cancer segment accounted for the largest share of the cancer biomarkers market in 2016
Based
on cancer type, the cancer biomarkers market is segmented into breast,
lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder,
non-Hodgkins lymphoma, kidney, and other cancers (such as cervical,
multiple myeloma, CNS, gastric, liver, pancreatic, oral cavity and
pharynx, stomach, and ovarian cancers). The breast cancer segment
accounted for the largest share of this market owing to the high and
growing prevalence of breast cancer, increasing awareness about breast
cancer, rising number of breast cancer screening programs, and growing
research on breast cancer.
The genetic biomarkers segment is expected to grow at the highest CAGR during the forecast period
Based
on biomarker type, the cancer biomarkers market is segmented into
genetic biomarkers, protein biomarkers, and other biomarkers (cell,
viral, and carbohydrate biomarkers). During the forecast period, the
genetic biomarkers segment is estimated to grow at the highest CAGR
majorly due to advancements in high-throughput technologies, such as
next-generation sequencing, which have enhanced the speed and accuracy
of genetic biomarker discovery and diagnosis.
The major players
operating in the cancer biomarkers market are Abbott (US), Affymetrix
(US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent
(US), Thermo Fisher (US), Merck (US), Becton Dickinson and Company (US),
and Hologic (US).
Request Free Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202
Comments
Post a Comment